22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
17:53 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Spyryx's SPX-101 improves lung function in Phase II CF trial

Spyryx Biosciences Inc. (Durham, N.C.) said high-dose SPX-101 given via a portable nebulizer led to a placebo-adjusted increase in percent predicted forced expiratory volume in 1 second (ppFEV1) from baseline to day 28 of 5.2%...
17:56 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Enterprise raises £29M series B

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...
08:17 , Apr 12, 2018 |  BC Extra  |  Financial News

Versant, Novartis Venture lead £29M round for Enterprise

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...
08:13 , Apr 12, 2018 |  BioCentury  |  Finance

Enterprise engages

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...
17:25 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Vertex reports Phase II data for VX-371 in CF

In its 3Q17 earnings report in October, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data From a Phase II trial in 142 cystic fibrosis patients ages 12 and older who are homozygous for the delta F508 CF...
21:40 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Spyryx starts Phase II for CF

Spyryx Biosciences Inc. (Durham, N.C.) began a Phase II trial evaluating SPX-101 in up to 78 patients with cystic fibrosis. The placebo-controlled, Canadian and European trial will evaluate 2 dose levels of twice-daily inhaled SPX-101...
21:45 , May 12, 2017 |  BioCentury  |  Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
01:40 , May 5, 2017 |  BC Week In Review  |  Clinical News

Spyryx reports positive Ph I safety data for SPX-101

In February, Spyryx Biosciences Inc. (Durham, N.C.) reported that single and multiple ascending doses of inhaled SPX-101 for 14 days were well tolerated and led to no dose-limiting toxicities (DLTs) in a Phase I trial...
16:07 , May 4, 2017 |  BC Week In Review  |  Company News

Parion grants Shire rights to dry eye candidate P-321

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution , an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million...